Quick Answer
CML treatment is guided by molecular monitoring. Learn what BCR-ABL1 levels mean and why adherence matters.
Medically reviewed by Dr. Sachita Baniya • NMC 20158 • Kathmandu Neurology Clinic & Cognitive Center
Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion gene, created by the Philadelphia chromosome. Tyrosine kinase inhibitors (TKIs) target this abnormal protein and have changed CML from a progressive cancer into a long-term condition for most patients.
How CML is diagnosed
CML is usually suspected when a blood count shows a high white cell count with a left shift and basophilia. Cytogenetics showing t(9;22) or a molecular test for BCR-ABL1 confirms the diagnosis. Baseline blood counts, spleen size, risk score and organ function are recorded before treatment.
What TKIs do
TKIs block the BCR-ABL1 tyrosine kinase and reduce the leukemic clone. They are taken regularly, often long term. The first choice depends on the patient's age, comorbidity, pregnancy plans, drug interactions and the side-effect profile.
Why monitoring is essential
Quantitative BCR-ABL1 testing measures the amount of leukemia transcript in the blood. It is checked at defined milestones — commonly at 3, 6 and 12 months, then periodically. The result tells the team whether the disease is responding, whether adherence is adequate and whether resistance is emerging.
- A falling BCR-ABL1 level indicates response.
- A rising level may indicate poor adherence, drug interactions or resistance.
- Persistent low-level detection is not the same as relapse.
- A deep molecular response may make some patients eligible for a supervised treatment-free remission trial.
Adherence and side effects
Missing doses is one of the commonest reasons for a poor response. Side effects such as fluid retention, rash, diarrhoea, muscle cramps or fatigue should be reported early — most can be managed with dose adjustment or a switch in therapy. Do not stop the drug on your own.
Can treatment be stopped?
Some patients with sustained deep molecular response can consider treatment-free remission, but only within a monitored programme. Stopping outside supervision risks relapse.
The bottom line
CML is a chronic disease for most patients, and the treatment works best when it is taken consistently and monitored systematically. Understanding your BCR-ABL1 trend is one of the most useful things you can do for your own care.
Frequently asked questions
Answers reviewed by Dr. Jitendra Prasad Yadav • MBBS, MD (Internal Medicine), FICN (Neurology), FCNV, FIHM • NMC 8029
CML is usually controlled long term with tyrosine kinase inhibitors rather than cured in the traditional sense. Some patients achieve sustained deep molecular responses and may be considered for treatment-free remission under close supervision.
Monitoring is usually performed at 3, 6 and 12 months after starting therapy, then periodically once a stable response is achieved. The exact schedule depends on the response and any treatment changes.
Most MPNs are acquired, not inherited. A family history is uncommon but exists in a small proportion.
MPNs increase the risk of arterial and venous clots, especially with older age, prior thrombosis and JAK2 mutation. Risk assessment guides treatment.
More: All FAQs → · Ask Dr. Jitendra →
Related articles
Measurable Residual Disease: Why 'No Blasts Seen' Is Not Always Remission
MRD testing can detect cancer cells below the limit of microscopy. Learn how it guides treatment in leukemia and myeloma.
Molecular Testing in Blood Cancer: What the Results Mean
Cytogenetics, FISH, PCR and next-generation sequencing guide diagnosis, risk and treatment in blood cancers.
AML Diagnosis Explained: From Blood Count to Genetic Risk
How acute myeloid leukemia is diagnosed, why bone marrow and genetic testing matter, and what the results mean for treatment.
Medical Disclaimer
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
References & Review
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
- International Classification of Headache Disorders, 3rd edition (ICHD-3).
- Harrison's Principles of Internal Medicine — Neurology sections.
- American Academy of Neurology guidelines for selected conditions (where applicable).
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.